Autologous Chondrocyte Injection for Disc Degeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively prevent or retard intervertebral disc degeneration, particularly in injured or herniated discs, leading to further degeneration and associated pain and mobility issues.
Innovation Solution
The method involves injecting mammalian connective tissue cells, such as chondrocytes or fibroblasts, into the intervertebral disc defect site, either alone or in combination with cells transduced with genes encoding proteins from the TGF-β superfamily, like TGF-β1, without the use of scaffolding structures, to promote regenerative functions and slow down degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment methods are used for intervertebral disc injury, then the treatment process is simple, but the disc continues to degenerate and loses height
Solution Approach 1:
The patent employs autologous chondrocytes that are harvested from the patient's own body, expanded in culture, and re-injected to regenerate disc tissue. This self-service approach eliminates the need for complex allogeneic cell matching and reduces immune rejection risks, while achieving effective disc height maintenance and degeneration prevention
Solution Approach 2:
The patent performs preliminary cell expansion in culture before injection, multiplying the number of viable chondrocytes available for treatment. This preliminary action ensures sufficient cell quantity is present to effectively regenerate disc matrix and maintain disc height, overcoming the limitation of small initial cell samples
2Ease of operation
If cell injection without scaffolding is used, then the treatment is less complex and more minimally invasive, but it requires precise cell delivery and retention
Solution Approach 1:
The patent uses a simple injection device to deliver cells directly into the disc space without requiring permanent scaffolding structures. The cells themselves serve as the temporary support, degrading naturally after performing their regenerative function, which simplifies the overall procedure and reduces complexity while maintaining effectiveness
3Adaptability or versatility
If allogeneic chondrocytes are used, then cell availability is increased, but immune rejection risk increases
Solution Approach 1:
The patent prioritizes using autologous chondrocytes harvested from the patient's own body (e.g., from ear cartilage or other non-critical areas). This self-service approach eliminates immune rejection concerns entirely, as the patient's own immune system recognizes the cells as self. Allogeneic cells are only considered when autologous sources are insufficient, and even then, immunosuppressive protocols are implemented
4Ease of manufacture
If disc degeneration is allowed to progress, then natural healing processes occur, but disc height is lost and pain increases
Solution Approach 1:
The patent performs preliminary cell expansion in culture to generate sufficient numbers of viable chondrocytes before injection. This preliminary action ensures that enough functional cells are present to actively regenerate disc matrix and maintain disc height, preventing the height loss that would otherwise occur during natural healing
Solution Approach 2:
The patent introduces cultured chondrocytes as an intermediary to facilitate disc regeneration. These cells serve as mediators that produce extracellular matrix and growth factors, actively maintaining disc height and preventing degeneration rather than passively allowing natural healing processes to occur
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively slows down or prevents intervertebral disc degeneration by maintaining disc height and morphology, as demonstrated by radiographic and MRI analyses, showing significant anti-degenerative effects in treated discs compared to controls.
Implementation Method 1
injecting a mammalian connective tissue cell into the intervertebral disc defect site... to promote regenerative functions
Implementation Method 2
transplanting the mammalian connective tissue cell into the intervertebral disc defect site... cells transduced with genes encoding proteins from the TGF-β superfamily
Data Source
AI summary
A method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site and a method for treating degenerated or injured intervertebral disc are disclosed. The methods include injecting a mammalian connective tissue cell into the intervertebral disc defect site.